News & Updates

HCV reinfection highest among people with ongoing injecting drug use
HCV reinfection highest among people with ongoing injecting drug use
14 Aug 2022

Reinfection with hepatitis C virus (HCV) is low among people receiving opioid agonist therapy (OAT) but appears to be at its peak during the first 24 weeks following treatment completion and among those with ongoing injecting drug use and needle‒syringe sharing, a study has found.

HCV reinfection highest among people with ongoing injecting drug use
14 Aug 2022
Treatment regimen based on small RNAi safe, effective in chronic hepatitis B
Treatment regimen based on small RNAi safe, effective in chronic hepatitis B
03 Aug 2022

In patients with chronic hepatitis B (CHB), treatment with the small interfering RNA JNJ-3989, in combination with a nucleos(t)ide analogue (NA), safely reduces levels of the hepatitis B surface antigen (HBsAg) for up to almost a year after the last dose, a new study has found.

Treatment regimen based on small RNAi safe, effective in chronic hepatitis B
03 Aug 2022